Results 111 to 120 of about 1,394,911 (165)

Overuse of thrombopoietin receptor agonists driven by suboptimal response is associated with myelofibrosis in pediatric immune thrombocytopenia. [PDF]

Haematologica
Ma J, Chen Z, Cheng X, Hu Y, Jiang J, Ma J, Lian H, Zhang L, Ma X, Lin X, Dong S, Li C, Yao W, Zhao S, Wei Y, Wu R.   +15 more
europepmc   +1 more source

Emerging data on thrombopoietin receptor agonists for management of chemotherapy-induced thrombocytopenia. [PDF]

Expert Rev Hematol, 2023
Song AB, Al-Samkari H.
europepmc   +1 more source

Thrombopoietin Receptor Agonists Plus Immunosuppressive Therapy in Aplastic Anaemia: A Systematic Review and Meta-Analysis. [PDF]

EJHaem
Ashrafi E, Young L, Fox LC, Ting SB, Wood EM, McQuilten ZK.   +5 more
europepmc   +1 more source

Preliminary experience with oral thrombopoietin-receptor agonists, primarily hetrombopag, in pediatric immune thrombocytopenia: a pilot single-center retrospective report. [PDF]

Transl Pediatr
Zhang M, Wang Y, Liang H, Zhang L.
europepmc   +1 more source

Thrombopoietin-receptor agonists for adult patients with immune thrombocytopenia: a narrative review and an approach for managing patients fasting intermittently. [PDF]

Front Cardiovasc Med, 2023
Yassin MA, Al-Rasheed M, Al-Khaboori M, Marashi M, Osman H, Wali Y, Al Kindi S, Alsayegh F, Provan D.   +8 more
europepmc   +1 more source

Acquired Amegakaryocytic Thrombocytopenia With Evolution Toward Aplastic Anemia Treated With Thrombopoietin Receptor Agonists: A Case Report. [PDF]

Case Rep Med
Jabbari-Zadeh F, Basharat MM, Chin-Yee B, Phua CW, Lam S, Xenocostas A, To E, Hsia CC.   +7 more
europepmc   +1 more source

Prolonged thrombocytopenia after CAR T-cell therapy: the role of thrombopoietin receptor agonists. [PDF]

Blood Adv, 2023
Drillet G, Lhomme F, De Guibert S, Manson G, Houot R.   +4 more
europepmc   +1 more source

Switching patients with immune thrombocytopenia (ITP) to avatrombopag from other thrombopoietin receptor agonists: The real-world experience of the Spanish ITP Group (GEPTI). [PDF]

Br J Haematol
Pascual-Izquierdo C, Bastida JM, Valcárcel D, Sánchez-González B, Mingot-Castellano ME, Canaro-Hirnyk M, Aguilar-Monserrate G, Ortiz-López A, Carbonell S, García-Lázaro S, Martín-Carrizosa A, Alonso-Martínez C, Alcalde-Mellado P, Pedrote-Amador B, Serrasolses-Alemany E, Remezal-Serrano M, Canet-Maldonado M, Gómez-Del-Castillo MD, Lasa-Eguialde M, García-Jaén P, Carrasco-Macedo S, González-Gascón-Y-Marín I, Zafra D, Fernández-Canal C, Piernas-Fontanilla S, Hernández-Vázquez L, Morales-Espino E, Cobo-Rodríguez T, Martínez-Carballeira D, González-Marugán P, Bolaños-Caderón E, Caballero-Navarro G, Revilla-Calvo N, Arquero-Portero T, Cervera M, Rodríguez-López M, Bañón-Soria J, Ramírez-López A, Álvarez-Román MT, Spanish ITP Group (GEPTI).   +39 more
europepmc   +1 more source

Thrombopoietin receptor agonists for chemotherapy-induced thrombocytopenia: a new solution for an old problem. [PDF]

Hematology Am Soc Hematol Educ Program, 2022
Al-Samkari H.
europepmc   +1 more source

No increased risk of acute myeloid leukemia in adults with primary immune thrombocytopenia treated with thrombopoietin receptor agonists: a French nationwide population-based study. [PDF]

Haematologica
Zadro Y, Lafaurie M, Sommet A, Lapeyre-Mestre M, Moulis G.   +4 more
europepmc   +1 more source